静脉注射免疫球蛋白改善儿童免疫性血小板减少症中凝血酶相关血小板功能
儿童免疫性血小板减少症(ITP)通常良性自限,但约28%发展为慢性ITP。一项纳入23例原发性ITP患儿的前瞻性研究发现,IVIg除升高血小板计数外,还可改善凝血酶诱导的血小板活化并增强凝血酶生成。
要点
- IVIg可能改善凝血酶诱导的血小板活化并增强凝血酶生成。
- 该前瞻性研究纳入23例原发性ITP患儿。
- 约28%的儿童ITP会发展为慢性ITP。
核心结论
- IVIg除升高血小板计数外,还可能改善凝血酶诱导的血小板活化并增强凝血酶生成。
研究设计与样本
- 前瞻性研究,纳入23例原发性ITP患儿。
主要发现
- IVIg可能改善凝血酶诱导的血小板活化并增强凝血酶生成。
局限性
- IVIg的一般作用机制仍未明确且存在争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Childhood immune thrombocytopenia (ITP) is an acquired haematological disorder characterized by low platelet counts, with a disease course which is usually benign and self-limiting within 3-12 months. An estimated 28%, however, continue to develop chronic ITP and may experience bleeding symptoms and an impaired quality of life. Treatment options in case of severe bleedings include corticosteroids, anti-D or intravenous immunoglobulins (IVIg). The general working mechanism of IVIg remains unresolved and a matter of debate. Schmugge et al now identify that IVIg may have the ability to improve thrombin-induced platelet activation and enhance thrombin generation in a prospective study of 23 children with primary ITP, demonstrating that besides increasing platelet counts IVIg can be efficacious on the level of thrombin-induced platelet activation and coagulation support. Commentary on: Schmugge et al. IVIg treatment increases thrombin activation of platelets and thrombin generation in paediatric patients with immune thrombocytopenia. Br J Haematol 2023;201:1209-1219.
引用
- Kapur R. Intravenous immunoglobulins ameliorate thrombin-related platelet functions in childhood immune thrombocytopenia. Br J Haematol. 2023. PMID: 36924289. doi:10.1111/bjh.18752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。